{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:36:13Z","timestamp":1791380173155,"version":"4.3.3"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T00:00:00Z","timestamp":1508976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017346","name":"Boehringer Ingelheim Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017346","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006453","name":"Taisho Toyama Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.jacl.2017.10.006","type":"journal-article","created":{"date-parts":[[2017,10,28]],"date-time":"2017-10-28T00:30:24Z","timestamp":1509150624000},"page":"173-184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":175,"title":["Efficacy and safety of pemafibrate (K-877), a\u00a0selective peroxisome proliferator-activated receptor \u03b1 modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1063-1979","authenticated-orcid":false,"given":"Shun","family":"Ishibashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koutaro","family":"Yokote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Suganami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuya","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2017.10.006_bib1","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Cholesterol Treatment Trialists C","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2017.10.006_bib2","doi-asserted-by":"crossref","first-page":"1K","DOI":"10.1016\/j.amjcard.2008.10.002","article-title":"The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia","volume":"102","author":"Fruchart","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2017.10.006_bib3","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.jacl.2017.10.006_bib4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4239\/wjd.v7.i5.74","article-title":"Use of fibrates in the metabolic syndrome: a review","volume":"7","author":"Shipman","year":"2016","journal-title":"World J Diabetes"},{"key":"10.1016\/j.jacl.2017.10.006_bib5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1\u2013full report","volume":"9","author":"Jacobson","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2017.10.006_bib6","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2015.09.002","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2","volume":"9","author":"Jacobson","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2017.10.006_bib7","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2017.10.006_bib8","first-page":"CD009580","article-title":"Fibrates for secondary prevention of cardiovascular disease and stroke","author":"Wang","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacl.2017.10.006_bib9","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jacl.2016.03.008","article-title":"Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia","volume":"10","author":"Maki","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2017.10.006_bib10","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/j.amjcard.2006.11.016","article-title":"Safety considerations with fibrate therapy","volume":"99","author":"Davidson","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2017.10.006_bib11","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2017.10.006_bib12","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.jacc.2012.07.049","article-title":"Effects of fibrates in kidney disease: a systematic review and meta-analysis","volume":"60","author":"Jun","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2017.10.006_bib13","doi-asserted-by":"crossref","first-page":"560","DOI":"10.7326\/0003-4819-156-8-201204170-00401","article-title":"New fibrate use and acute renal outcomes in elderly adults: a population-based study","volume":"156","author":"Zhao","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2017.10.006_bib14","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1161\/01.ATV.6.6.670","article-title":"Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia","volume":"6","author":"Brown","year":"1986","journal-title":"Arteriosclerosis"},{"issue":"Suppl 1","key":"10.1016\/j.jacl.2017.10.006_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/21548331.1988.11703636","article-title":"Focus on fenofibrate","volume":"23","author":"Brown","year":"1988","journal-title":"Hosp Pract (Off Ed)"},{"key":"10.1016\/j.jacl.2017.10.006_bib16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1475-2840-12-82","article-title":"Selective peroxisome proliferator-activated receptor alpha modulators (SPPARMalpha): the next generation of peroxisome proliferator-activated receptor alpha-agonists","volume":"12","author":"Fruchart","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacl.2017.10.006_bib17","doi-asserted-by":"crossref","first-page":"754","DOI":"10.5551\/jat.28720","article-title":"Transcriptome analysis of K-877 (a novel selective PPARalpha modulator (SPPARMalpha))-regulated genes in primary human hepatocytes and the mouse liver","volume":"22","author":"Raza-Iqbal","year":"2015","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacl.2017.10.006_bib18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2016.02.029","article-title":"Effects of K-877, a novel selective PPARalpha modulator (SPPARMalpha), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial","volume":"249","author":"Ishibashi","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2017.10.006_bib19","first-page":"794","article-title":"Definition and diagnostic criteria of metabolic syndrome","volume":"94","year":"2005","journal-title":"Nippon Naika Gakkai Zasshi"},{"key":"10.1016\/j.jacl.2017.10.006_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5551\/jat.18473","article-title":"Metabolic syndrome","volume":"21","author":"Teramoto","year":"2014","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacl.2017.10.006_bib21","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/clinchem\/44.3.522","article-title":"Homogeneous assay for measuring low-density lipoprotein cholesterol in serum with triblock copolymer and alpha-cyclodextrin sulfate","volume":"44","author":"Sugiuchi","year":"1998","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2017.10.006_bib22","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1093\/clinchem\/48.11.1946","article-title":"Differential reactivity of two homogeneous LDL-cholesterol methods to LDL and VLDL subfractions, as demonstrated by ultracentrifugation and HPLC","volume":"48","author":"Usui","year":"2002","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2017.10.006_bib23","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2017.10.006_bib24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2017.10.006_bib25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"Jorgensen","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2017.10.006_bib26","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1172\/JCI112713","article-title":"Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in\u00a0vivo","volume":"78","author":"Ginsberg","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2017.10.006_bib27","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.atherosclerosis.2017.03.032","article-title":"Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), in combination with statin treatment: two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia","volume":"261","author":"Arai","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2017.10.006_bib28","doi-asserted-by":"crossref","first-page":"42477","DOI":"10.1038\/srep42477","article-title":"Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis","volume":"7","author":"Honda","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacl.2017.10.006_bib29","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1210\/en.2006-1168","article-title":"The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21","volume":"148","author":"Kharitonenkov","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.jacl.2017.10.006_bib30","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11010-016-2774-2","article-title":"FGF21 ameliorates nonalcoholic fatty liver disease by inducing autophagy","volume":"420","author":"Zhu","year":"2016","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.jacl.2017.10.006_bib31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0002-9343(87)90876-X","article-title":"Potential use of fenofibrate and other fibric acid derivatives in the clinic","volume":"83","author":"Brown","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.jacl.2017.10.006_bib32","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1053\/j.ajkd.2008.01.014","article-title":"Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people","volume":"51","author":"Ansquer","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacl.2017.10.006_bib33","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.2337\/dc11-1811","article-title":"Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants","volume":"35","author":"Mychaleckyj","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2017.10.006_bib34","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1159\/000064083","article-title":"Fenofibrate increases creatininemia by increasing metabolic production of creatinine","volume":"92","author":"Hottelart","year":"2002","journal-title":"Nephron"},{"key":"10.1016\/j.jacl.2017.10.006_bib35","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1124\/jpet.107.129197","article-title":"Fenofibrate treatment of diabetic rats reduces nitrosative stress, renal cyclooxygenase-2 expression, and enhanced renal prostaglandin release","volume":"324","author":"Chen","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jacl.2017.10.006_bib36","first-page":"896","article-title":"Antilipidemic drugs. Part 4: the metabolic fate of the hypolipidemic agent isopropyl-[4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl]-protionate (LF 178) in rats, dog and man","volume":"26","author":"Brodie","year":"1976","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.jacl.2017.10.006_bib37","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00228-009-0723-7","article-title":"Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report","volume":"65","author":"Wu","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jacl.2017.10.006_bib38","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1681\/ASN.2005101085","article-title":"Chronic kidney disease and mortality risk: a systematic review","volume":"17","author":"Tonelli","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacl.2017.10.006_bib39","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2017.10.006_bib40","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0140-6736(05)77220-2","article-title":"Lipid-lowering drugs and homocysteine","volume":"353","author":"de Lorgeril","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2017.10.006_bib41","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/bmj.325.7374.1202","article-title":"Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis","volume":"325","author":"Wald","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2017.10.006_bib42","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1055\/s-0038-1649476","article-title":"Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia","volume":"70","author":"Branchi","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacl.2017.10.006_bib43","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood.V93.9.2991.409k03_2991_2998","article-title":"Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha","volume":"93","author":"Kockx","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jacl.2017.10.006_bib44","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3945\/ajcn.112.044545","article-title":"Common genetic loci influencing plasma homocysteine concentrations and their effect on risk of coronary artery disease","volume":"98","author":"van Meurs","year":"2013","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jacl.2017.10.006_bib45","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1161\/CIRCULATIONAHA.113.002251","article-title":"Multiethnic meta-analysis of genome-wide association studies in >100 000 subjects identifies 23 fibrinogen-associated Loci but no strong evidence of a causal association between circulating fibrinogen and cardiovascular disease","volume":"128","author":"Sabater-Lleal","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2017.10.006_bib46","unstructured":"ClinicalTrials.gov NCT03071692. \u201cPemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)\u201d. Available at: https:\/\/clinicaltrials.gov\/show\/NCT03071692. Accessed June 15, 2017."}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193328741730466X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193328741730466X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:34:21Z","timestamp":1761831261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193328741730466X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S193328741730466X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2017.10.006","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of pemafibrate (K-877), a\u00a0selective peroxisome proliferator-activated receptor \u03b1 modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2017.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 National Lipid Association.","name":"copyright","label":"Copyright"}]}}